In the latest session, The Chemours Company (NYSE: CC) closed at $28.01 down -1.37% from its previous closing price of $28.40. In other words, the price has decreased by -$0.39 from its previous closing price. On the day, 736689 shares were traded.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Ratios:
For a deeper understanding of The Chemours Company’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.17 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 22.22. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 1.80. In the meantime, Its Debt-to-Equity ratio is 2.95 whereas as Long-Term Debt/Eq ratio is at 2.93.
Upgrades & Downgrades
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 06 when Bellezza Alisha sold 27,716 shares for $35.47 per share. The transaction valued at 983,087 led to the insider holds 43,931 shares of the business.
Sparks Edwin C sold 22,142 shares of CC for $965,170 on Jun 07. The President, Titan Tech Chem Sol now owns 101,038 shares after completing the transaction at $43.59 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CC now has a Market Capitalization of 4.33B and an Enterprise Value of 7.09B. As of this moment, The’s Price-to-Earnings (P/E) ratio for their current fiscal year is 9.06, and their Forward P/E ratio for the next fiscal year is 5.11. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.86. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.64 while its Price-to-Book (P/B) ratio in mrq is 3.40. Its current Enterprise Value per Revenue stands at 1.08 whereas that against EBITDA is 6.48.
Stock Price History:
Over the past 52 weeks, CC has reached a high of $44.95, while it has fallen to a 52-week low of $23.58. The 50-Day Moving Average of the stock is 29.09, while the 200-Day Moving Average is calculated to be 31.27.
Shares Statistics:
For the past three months, CC has traded an average of 1.15M shares per day and 1.06M over the past ten days. A total of 149.00M shares are outstanding, with a floating share count of 146.83M. Insiders hold about 0.10% of the company’s shares, while institutions hold 76.70% stake in the company. Shares short for CC as of May 14, 2023 were 4.52M with a Short Ratio of 4.52M, compared to 4.21M on Apr 13, 2023. Therefore, it implies a Short% of Shares Outstanding of 3.03% and a Short% of Float of 4.06%.
Dividends & Splits
According to the company, the forward annual dividend rate for CC is 1.00, from 1.00 in the trailing year. Against a Trailing Annual Dividend Yield of 3.52%, it implies a Forward Annual Dividend Yield of 3.52%. The stock’s 5-year Average Dividend Yield is 3.93.
Earnings Estimates
There are 8 different market analysts currently analyzing its stock. On average, analysts expect EPS of $1.14 for the current quarter, with a high estimate of $1.2 and a low estimate of $1.05, while EPS last year was $1.89. The consensus estimate for the next quarter is $1.25, with high estimates of $1.41 and low estimates of $1.14.
Analysts are recommending an EPS of between $4.63 and $3.95 for the fiscal current year, implying an average EPS of $4.22. EPS for the following year is $5.48, with 10 analysts recommending between $7.11 and $3.95.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $1.71B this quarter.It ranges from a high estimate of $1.77B to a low estimate of $1.67B. As of the current estimate, The Chemours Company’s year-ago sales were $1.92B, an estimated decrease of -11.00% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $1.78B, an increase of 0.20% over than the figure of -$11.00% in the same quarter last year. There is a high estimate of $1.89B for the next quarter, whereas the lowest estimate is $1.72B.
A total of 8 analysts have provided revenue estimates for CC’s current fiscal year. The highest revenue estimate was $6.82B, while the lowest revenue estimate was $6.43B, resulting in an average revenue estimate of $6.63B. In the same quarter a year ago, actual revenue was $6.79B, down -2.40% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $7.12B in the next fiscal year. The high estimate is $7.58B and the low estimate is $6.52B. The average revenue growth estimate for next year is up 7.40% from the average revenue estimate for this year.
